SCHEDULE: StemPoint Capital Files Schedule 13G Amendment

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly filed an amendment to their Schedule 13G, reporting 0 shares beneficially owned in Faeth Therapeutics, Inc.

Summary

• This filing is an amendment to a Schedule 13G, a filing required for beneficial ownership of securities.
• The reporting persons are StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross.
• They are jointly filing this amendment concerning Faeth Therapeutics, Inc.
• As of June 30, 2026, the reporting persons collectively beneficially own 0 shares of Faeth Therapeutics, Inc. common stock.
• This represents 0.0% of the class of securities.
• The calculation is based on 25,778,754 shares of common stock reported as outstanding on June 15, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily administrative, with no new financial information or strategic shifts disclosed.

Negatives

• The reporting persons hold no shares of Faeth Therapeutics, Inc. common stock, indicating no current investment or control interest.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or other entities that acquire a significant stake in a public company. The absence of any beneficial ownership in this amendment suggests a change in investment strategy or a lack of prior holdings.

Stakeholder Impact

• Shareholders of Faeth Therapeutics, Inc. may note the lack of investment from StemPoint Capital, which could be interpreted in various ways depending on the market's perception of StemPoint Capital.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Faeth Therapeutics, StemPoint Capital